Evidence Snapshot

Glutamate [NMDA] receptor

CHEMBL2094124 PROTEIN COMPLEX GROUP Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:47Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 6:25 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2094124

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Glutamate [NMDA] receptor as ChEMBL target CHEMBL2094124, mapped to UniProt Q05586. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Glutamate [NMDA] receptor

PROTEIN COMPLEX GROUP · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL2094124

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

Q05586

Glutamate receptor ionotropic, NMDA 1

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Glutamate [NMDA] receptor matters

As of 2026-09-13

Glutamate [NMDA] receptor is reviewed as Glutamate receptor ionotropic, NMDA 1 (UniProt Q05586); Glutamate [NMDA] receptor shows approved-linked disease relevance led by major depressive disorder. 5 more disease programs remain visible in the same review block.; 6 linked drugs keep this evidence frame grounded.; the current evidence base includes 8 approved drugs, 677 compounds, and 176 assays, with lead potency reaching pChEMBL 9.3.

Protein context

Glutamate receptor ionotropic, NMDA 1

Glutamate receptor ionotropic, NMDA 1 Sequence length is 938 aa.

Review this target as Glutamate [NMDA] receptor, mapped to UniProt Q05586. ChEMBL maps the protein component as Glutamate receptor ionotropic, NMDA 1. Sequence length is 938 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt Q05586 Protein

Disease context

major depressive disorder

Glutamate [NMDA] receptor shows approved-linked disease relevance led by major depressive disorder. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include APIMOSTINEL, AV-101, ESKETAMINE HYDROCHLORIDE.

Start review with major depressive disorder because it currently carries approved-linked support. Linked drugs include APIMOSTINEL, AV-101, ESKETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 6 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 8 approved drugs, 677 compounds, and 176 assays for this target. The dominant activity type is IC50. CHEMBL276708 is the current potency anchor at pChEMBL 9.3.

Use CHEMBL276708 as the tractability anchor when discussing potency (pChEMBL 9.3).

Activity source · ChEMBL 36 via Core Engine

8 approved pChEMBL 9.3

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Glutamate [NMDA] receptor matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q05586, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why major depressive disorder is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

677

Total Compounds

176

Total Assays

Approved Drugs

IC50: 616.0, KI: 200.0, EC50: 1.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL276708	9.3	IC50	—
No preferred name CHEMBL12513	9.1	IC50	—
No preferred name CHEMBL39881	9.0	Ki	—
No preferred name CHEMBL12804	9.0	IC50	—
No preferred name CHEMBL12242	8.9	IC50	—